分化型甲状腺癌-话题@MedSci

#分化型甲状腺癌#

32篇内容 | 2076人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2217480, encodeId=2970221e48075, content=<a href='/topic/show?id=6a3f633e79a' target=_blank style='color:#2F92EE;'>#死亡率#</a> <a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a> <a href='/topic/show?id=eac36239102' target=_blank style='color:#2F92EE;'>#桥本甲状腺炎#</a>, objectTitle=Endocrinol Metab：桥本甲状腺炎与分化型甲状腺癌患者的死亡率meta分析, objectType=article, longId=836830, objectId=8e0a83683029, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240722/1721617793450_92910.jpg, objectUrl=/article/show_article.do?id=8e0a83683029, replyNumber=0, likeNumber=49, createdTime=2024-07-30, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=8e0a83683029, moduleTitle=Endocrinol Metab：桥本甲状腺炎与分化型甲状腺癌患者的死亡率meta分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e0a83683029)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2216795, encodeId=238b2216e95e7, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a> <a href='/topic/show?id=341f25314f1' target=_blank style='color:#2F92EE;'>#仑伐替尼#</a> <a href='/topic/show?id=34b54848271' target=_blank style='color:#2F92EE;'>#帕博利珠单抗#</a> <a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=CLIN CANCER RES | 仑伐替尼与帕博利珠单抗联合治疗碘难治性分化型甲状腺癌的疗效和安全性分析：一项Ⅱ期临床研究, objectType=article, longId=836099, objectId=712b83609958, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240724/1721830700243_6145188.png, objectUrl=/article/show_article.do?id=712b83609958, replyNumber=0, likeNumber=51, createdTime=2024-07-25, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=712b83609958, moduleTitle=CLIN CANCER RES | 仑伐替尼与帕博利珠单抗联合治疗碘难治性分化型甲状腺癌的疗效和安全性分析：一项Ⅱ期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=712b83609958)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1322592, encodeId=24ab132259283, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, objectTitle=Cancers ：累积剂量的放射性碘对伴有1型糖尿病的分化型甲状腺癌患者的心血管效应, objectType=article, longId=728777, objectId=732ee28777a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=732ee28777a4, replyNumber=0, likeNumber=92, createdTime=2022-06-08, rootId=0, userName=dzx0922889, userId=05a2499, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=732ee28777a4, moduleTitle=Cancers ：累积剂量的放射性碘对伴有1型糖尿病的分化型甲状腺癌患者的心血管效应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=732ee28777a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322591, encodeId=57e91322591c5, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, objectTitle=J Clin Oncol：Selumetinib联合放射性碘治疗高风险的分化型甲状腺癌, objectType=article, longId=299552, objectId=e37a29955264, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e37a29955264, replyNumber=0, likeNumber=78, createdTime=2022-02-25, rootId=0, userName=dzx0922889, userId=05a2499, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e37a29955264, moduleTitle=J Clin Oncol：Selumetinib联合放射性碘治疗高风险的分化型甲状腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e37a29955264)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322590, encodeId=76c813225904f, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, objectTitle=JAMA Oncol：阿帕替尼 vs安慰剂治疗局部晚期或转移性、放射性碘难治分化型甲状腺癌患者的疗效: 随机临床研究REALITY, objectType=article, longId=292261, objectId=67d0292261ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67d0292261ff, replyNumber=0, likeNumber=84, createdTime=2021-12-21, rootId=0, userName=dzx0922889, userId=05a2499, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67d0292261ff, moduleTitle=JAMA Oncol：阿帕替尼 vs安慰剂治疗局部晚期或转移性、放射性碘难治分化型甲状腺癌患者的疗效: 随机临床研究REALITY, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=67d0292261ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322589, encodeId=8069132258963, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, objectTitle=Clin Cancer Res：3期| 乐伐替尼在中国放射性碘难治性分化型甲状腺癌患者中的疗效, objectType=article, longId=215211, objectId=48cb2152117d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48cb2152117d, replyNumber=0, likeNumber=0, createdTime=2021-08-04, rootId=0, userName=dzx0922889, userId=05a2499, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48cb2152117d, moduleTitle=Clin Cancer Res：3期| 乐伐替尼在中国放射性碘难治性分化型甲状腺癌患者中的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48cb2152117d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322588, encodeId=3e51132258829, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, objectTitle=JCEM：TSH抑制疗法对分化型甲状腺癌患者骨密度的影响, objectType=article, longId=214790, objectId=d6f2214e90db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d6f2214e90db, replyNumber=0, likeNumber=88, createdTime=2021-07-27, rootId=0, userName=dzx0922889, userId=05a2499, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d6f2214e90db, moduleTitle=JCEM：TSH抑制疗法对分化型甲状腺癌患者骨密度的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d6f2214e90db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322587, encodeId=7327132258e0f, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, objectTitle=Eur J Cancer：乐伐替尼可显著延长放射性碘难治性分化型甲状腺癌患者的存活期，即使已发生了肺转移！, objectType=article, longId=207377, objectId=cb8020e3772b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb8020e3772b, replyNumber=0, likeNumber=83, createdTime=2021-02-22, rootId=0, userName=dzx0922889, userId=05a2499, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb8020e3772b, moduleTitle=Eur J Cancer：乐伐替尼可显著延长放射性碘难治性分化型甲状腺癌患者的存活期，即使已发生了肺转移！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb8020e3772b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322586, encodeId=116913225861e, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, objectTitle=JCEM：小儿和青少年分化型甲状腺癌的远处转移, objectType=article, longId=199729, objectId=d361199e29ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d361199e29ae, replyNumber=0, likeNumber=97, createdTime=2020-08-22, rootId=0, userName=dzx0922889, userId=05a2499, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d361199e29ae, moduleTitle=JCEM：小儿和青少年分化型甲状腺癌的远处转移, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d361199e29ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322585, encodeId=80091322585a1, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, objectTitle=Thyroid：抗甲状腺球蛋白抗体作为分化型甲状腺癌的预后标志物, objectType=article, longId=193324, objectId=a4b31933243e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a4b31933243e, replyNumber=0, likeNumber=90, createdTime=2020-05-03, rootId=0, userName=dzx0922889, userId=05a2499, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a4b31933243e, moduleTitle=Thyroid：抗甲状腺球蛋白抗体作为分化型甲状腺癌的预后标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a4b31933243e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322584, encodeId=8a6d1322584d0, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, objectTitle=Thyroid：放射疗法对分化型甲状腺癌女性卵巢储备的影响, objectType=article, longId=187858, objectId=9f5618e858ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f5618e858ef, replyNumber=0, likeNumber=76, createdTime=2020-02-13, rootId=0, userName=dzx0922889, userId=05a2499, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f5618e858ef, moduleTitle=Thyroid：放射疗法对分化型甲状腺癌女性卵巢储备的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f5618e858ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322583, encodeId=fc19132258323, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, objectTitle=JCEM：BMI对分化型甲状腺癌侵袭性表现和临床结局的潜在影响, objectType=article, longId=185507, objectId=c12018550e76, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c12018550e76, replyNumber=0, likeNumber=72, createdTime=2020-01-02, rootId=0, userName=dzx0922889, userId=05a2499, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c12018550e76, moduleTitle=JCEM：BMI对分化型甲状腺癌侵袭性表现和临床结局的潜在影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c12018550e76)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322582, encodeId=3487132258293, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, objectTitle=分化型甲状腺癌术后 131 I治疗前评估专家共识, objectType=article, longId=182411, objectId=e6dd182411d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6dd182411d0, replyNumber=0, likeNumber=0, createdTime=2019-11-06, rootId=0, userName=dzx0922889, userId=05a2499, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6dd182411d0, moduleTitle=分化型甲状腺癌术后 131 I治疗前评估专家共识, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6dd182411d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322581, encodeId=65f8132258114, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, objectTitle=碘难治性分化型甲状腺癌的诊治管理共识（2019年版）, objectType=article, longId=176280, objectId=e8e91e6280a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8e91e6280a7, replyNumber=0, likeNumber=65, createdTime=2019-07-28, rootId=0, userName=dzx0922889, userId=05a2499, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8e91e6280a7, moduleTitle=碘难治性分化型甲状腺癌的诊治管理共识（2019年版）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8e91e6280a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322580, encodeId=941c132258077, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, objectTitle=2018 CSCO临床指南：持续/复发及转移性分化型甲状腺癌的诊断和治疗（英文版）, objectType=article, longId=165743, objectId=f767165e430e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f767165e430e, replyNumber=0, likeNumber=72, createdTime=2019-05-10, rootId=0, userName=dzx0922889, userId=05a2499, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f767165e430e, moduleTitle=2018 CSCO临床指南：持续/复发及转移性分化型甲状腺癌的诊断和治疗（英文版）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f767165e430e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322579, encodeId=4ad713225e9f9, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, objectTitle=2018 意大利共识：分化型甲状腺癌的诊断和治疗, objectType=article, longId=137956, objectId=856713e956bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=856713e956bf, replyNumber=0, likeNumber=62, createdTime=2018-05-13, rootId=0, userName=dzx0922889, userId=05a2499, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=856713e956bf, moduleTitle=2018 意大利共识：分化型甲状腺癌的诊断和治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=856713e956bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322578, encodeId=7e4013225e8c6, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, objectTitle=血清 TSH，Tg，TgAb：评估分化型甲状腺癌的三驾马车, objectType=article, longId=137292, objectId=757113e292c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=757113e292c9, replyNumber=0, likeNumber=83, createdTime=2018-05-06, rootId=0, userName=dzx0922889, userId=05a2499, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=757113e292c9, moduleTitle=血清 TSH，Tg，TgAb：评估分化型甲状腺癌的三驾马车, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=757113e292c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322577, encodeId=efd613225e7ba, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, objectTitle=JCEM：低危分化型甲状腺癌患者应不应该接受放射性碘？, objectType=article, longId=123843, objectId=5097123843b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5097123843b3, replyNumber=0, likeNumber=76, createdTime=2017-12-19, rootId=0, userName=dzx0922889, userId=05a2499, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5097123843b3, moduleTitle=JCEM：低危分化型甲状腺癌患者应不应该接受放射性碘？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5097123843b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322576, encodeId=d04013225e609, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, objectTitle=美国甲状腺学会《儿童甲状腺结节与分化型甲状腺癌诊治指南》解读, objectType=article, longId=113441, objectId=c226113441bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c226113441bb, replyNumber=0, likeNumber=72, createdTime=2017-09-22, rootId=0, userName=dzx0922889, userId=05a2499, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c226113441bb, moduleTitle=美国甲状腺学会《儿童甲状腺结节与分化型甲状腺癌诊治指南》解读, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c226113441bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322575, encodeId=654013225e558, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, objectTitle=JCO：抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效, objectType=article, longId=110822, objectId=f90d11082200, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f90d11082200, replyNumber=0, likeNumber=86, createdTime=2017-08-26, rootId=0, userName=dzx0922889, userId=05a2499, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f90d11082200, moduleTitle=JCO：抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f90d11082200)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

分化型甲状腺癌

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#死亡率# #分化型甲状腺癌# #桥本甲状腺炎#

Endocrinol Metab：桥本甲状腺炎与分化型甲状腺癌患者的死亡率meta分析

2024-07-30发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#分化型甲状腺癌# #仑伐替尼# #帕博利珠单抗# #II期临床研究#

CLIN CANCER RES | 仑伐替尼与帕博利珠单抗联合治疗碘难治性分化型甲状腺癌的疗效和安全性分析：一项Ⅱ期临床研究

2024-07-25发表于上海

dzx0922889 (审核中...)

前往app查看评论内容

#分化型甲状腺癌#

Cancers ：累积剂量的放射性碘对伴有1型糖尿病的分化型甲状腺癌患者的心血管效应

2022-06-08

dzx0922889 (审核中...)

前往app查看评论内容

#分化型甲状腺癌#

J Clin Oncol：Selumetinib联合放射性碘治疗高风险的分化型甲状腺癌

2022-02-25

dzx0922889 (审核中...)

前往app查看评论内容

#分化型甲状腺癌#

JAMA Oncol：阿帕替尼 vs安慰剂治疗局部晚期或转移性、放射性碘难治分化型甲状腺癌患者的疗效: 随机临床研究REALITY

2021-12-21

dzx0922889 (审核中...)

前往app查看评论内容

#分化型甲状腺癌#

Clin Cancer Res：3期| 乐伐替尼在中国放射性碘难治性分化型甲状腺癌患者中的疗效

2021-08-04

dzx0922889 (审核中...)

前往app查看评论内容

#分化型甲状腺癌#

JCEM：TSH抑制疗法对分化型甲状腺癌患者骨密度的影响

2021-07-27

dzx0922889 (审核中...)

前往app查看评论内容

#分化型甲状腺癌#

Eur J Cancer：乐伐替尼可显著延长放射性碘难治性分化型甲状腺癌患者的存活期，即使已发生了肺转移！

2021-02-22

dzx0922889 (审核中...)

前往app查看评论内容

#分化型甲状腺癌#

JCEM：小儿和青少年分化型甲状腺癌的远处转移

2020-08-22

dzx0922889 (审核中...)

前往app查看评论内容

#分化型甲状腺癌#

Thyroid：抗甲状腺球蛋白抗体作为分化型甲状腺癌的预后标志物

2020-05-03

dzx0922889 (审核中...)

前往app查看评论内容

#分化型甲状腺癌#

Thyroid：放射疗法对分化型甲状腺癌女性卵巢储备的影响

2020-02-13

dzx0922889 (审核中...)

前往app查看评论内容

#分化型甲状腺癌#

JCEM：BMI对分化型甲状腺癌侵袭性表现和临床结局的潜在影响

2020-01-02

dzx0922889 (审核中...)

前往app查看评论内容

#分化型甲状腺癌#

分化型甲状腺癌术后 131 I治疗前评估专家共识

2019-11-06

dzx0922889 (审核中...)

前往app查看评论内容

#分化型甲状腺癌#

碘难治性分化型甲状腺癌的诊治管理共识（2019年版）

2019-07-28

dzx0922889 (审核中...)

前往app查看评论内容

#分化型甲状腺癌#

2018 CSCO临床指南：持续/复发及转移性分化型甲状腺癌的诊断和治疗（英文版）

2019-05-10

dzx0922889 (审核中...)

前往app查看评论内容

#分化型甲状腺癌#

2018 意大利共识：分化型甲状腺癌的诊断和治疗

2018-05-13

dzx0922889 (审核中...)

前往app查看评论内容

#分化型甲状腺癌#

血清 TSH，Tg，TgAb：评估分化型甲状腺癌的三驾马车

2018-05-06

dzx0922889 (审核中...)

前往app查看评论内容

#分化型甲状腺癌#

JCEM：低危分化型甲状腺癌患者应不应该接受放射性碘？

2017-12-19

dzx0922889 (审核中...)

前往app查看评论内容

#分化型甲状腺癌#

美国甲状腺学会《儿童甲状腺结节与分化型甲状腺癌诊治指南》解读

2017-09-22

dzx0922889 (审核中...)

前往app查看评论内容

#分化型甲状腺癌#

JCO：抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效

2017-08-26

科室
- - 订阅+
  - 更多科室
工具
服务